SCHEMBL4324784

SCHEMBL4324784

Fc1c(CBr)cccc1Cc1ccccc1

nearest known ligand 0.50

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
TRPA1 O75762 1/20 0.44
ALDH1A1 P00352 1/20 0.44
TSHR P16473 1/20 0.44
HTR2A P28223 1/20 0.42
CALM1 P0DP23 1/20 0.42
BCL2 P10415 1/20 0.41
BCL2L1 Q07817 1/20 0.41
ALOX5 P09917 1/20 0.40
OPRM1 P35372 2/20 0.38
OPRK1 P41145 2/20 0.38
L3MBTL1 Q9Y468 1/20 0.38
CTRC Q99895 1/20 0.37
TDP1 Q9NUW8 1/20 0.37
CYP1A2 P05177 1/20 0.37
CYP3A4 P08684 1/20 0.37
CYP2D6 P10635 1/20 0.37
CYP2C9 P11712 1/20 0.37
CYP2C19 P33261 1/20 0.37
HPGD P15428 1/20 0.36
SMN1; SMN2 Q16637 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL960397 0.82 GABRA1 (0.36) TRPA1ALDH1A1TSHR
SCHEMBL695542 0.81 HTR2A (0.56) TRPA1ALDH1A1TSHRHTR2ACALM1
SCHEMBL8045395 0.80 BCL2 (0.55) HTR2ACALM1BCL2BCL2L1ALOX5
SCHEMBL3306943 0.79 HTR2A (0.50) ALDH1A1HTR2ACALM1BCL2BCL2L1
SCHEMBL13545700 0.78 CALM1 (0.44) TSHRHTR2ACALM1BCL2BCL2L1
SCHEMBL23428908 0.76 HTR2A (0.47) HTR2ACALM1BCL2BCL2L1ALOX5
SCHEMBL10653799 0.76 HTR2A (0.42) HTR2ACALM1BCL2BCL2L1ALOX5
SCHEMBL28579571 0.75 ALOX5 (0.47) ALDH1A1HTR2ACALM1BCL2BCL2L1
SCHEMBL18071830 0.74 PNMT (0.43)
SCHEMBL5156201 0.73 SLC5A1 (0.41) ALDH1A1HTR2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20090069340-A1 Pyrazolone Compounds As Metabotropic Glutamate Receptor Agonists For The Treatment Of Neurological And Psychiatric Disorders ASTRAZENECA AB (SE) 2009-03-12 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090069340-A1 Pyrazolone Compounds As Metabotropic Glutamate Receptor Agonists For The Treatment Of Neurological And Psychiatric Disorders GRIN1, GRM1, GRIN3A TRPA1 842/4885ALDH1A1 1785/4885TSHR 240/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.